MS241220C132000
- 0.01
- -0.01-50.00%
Morgan Stanley Newsroom
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Express News | Morgan Stanley - Board to Reduce Size to 13 Directors Effective Jan 1, 2025
Express News | Morgan Stanley - Stephen Luczo Resigns From Morgan Stanley Board Effective Dec 31, 2024
9 Financials Stocks Whale Activity In Today's Session
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Week's Best: What to Do With Idle Cash -- Barrons.com
Morgan Stanley's (NYSE:MS) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Alternative "Blind Box" is on fire! Banco Santander (SAN.US) seizes the opportunity to sell off 60 billion euros in risk Assets.
Banco Santander is able to remove 60 billion euros (equivalent to 63 billion dollars) of risk-weighted Assets from its balance sheet this year.
Morgan Stanley: The sale of Intime by BABA-SW may bring potential special dividends.
Morgan Stanley released a research report stating that Alibaba-SW (09988) is selling Intime for 7.4 billion yuan, which is expected to result in an accounting loss of 9.3 billion yuan. Morgan Stanley believes that the cash proceeds may contribute to a potential special dividend before the end of this fiscal year, similar to the group’s actions last year. Morgan Stanley thinks that the sale of Intime aligns with the management’s strategy to focus on core Business and potentially divest from offline Retail Trade. Considering the well-known decline in asset value, the recorded loss should not surprise the market, especially since the loss is non-cash and non-recurring.
Morgan Stanley: Maintains "Shareholding" rating for HANSOH PHARMA with a Target Price of 24 Hong Kong dollars.
Morgan Stanley released a research report stating that it gives HANSOH PHARMA (03692) a "Shareholding" rating, with a Target Price of HK$24. HANSOH PHARMA announced that it has entered into a Global exclusive licensing agreement with Merck, granting them the Global exclusive license for the development, production, and commercialization of the preclinical oral small molecule GLP-1 receptor agonist HS-10535, involving an upfront payment of $0.112 billion, as well as milestone payments and royalties based on product sales of up to $1.9 billion. Morgan Stanley believes that the news will have a positive reaction on the stock price, although HS-10535 has historically received little attention from investors, which may not significantly affect the valuation of HANSOH PHARMA.
Trump's tariff plan is unpopular! More than half of the USA population opposes imposing taxes on commodities from Mexico.
①The plan of the USA's incoming president Trump to impose tariffs does not seem to be popular among the public. According to a poll, 51% of USA voters oppose imposing tariffs on commodities from Mexico, Canada, and China; ②Standard & Poor's states that USA tariffs will increase inflation rates and reduce economic output, while some citizens and businesses are stockpiling goods due to tariff concerns, leading to a significant increase in throughput at the ports of Los Angeles and Long Beach in November.
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Shares of Financial Companies Are Trading Lower Amid Overall Market Weakness Following the Fed's Rate Decision to Cut Rates by 25 Basis Points.
Express News | Shares of Financial Companies Are Trading Lower Amid Overall Market Weakness Following the Fed's Rate Decision to Cut Rates by 25 Basis Points
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Macquarie states that the pessimistic expectations for next year's oil prices may need to be reassessed.
Wall Street's pessimistic expectations for the oil market in 2025 have begun to show cracks. Institutions like Macquarie indicate that weaker production growth and tightening supply balance have raised doubts about next year's pessimistic forecasts. In a report to clients led by Analyst Vikas Dwivedi, Macquarie stated that as 2024 comes to a close, crude oil inventories have only seen a slight increase, having been predicted to "increase significantly" earlier this year. On the supply side, Macquarie expects that OPEC+ will not restore production, and that production from the USA will not see significant increases. Few traders are willing to short Brent crude oil at $70 per barrel, as
Consumer Finance Watchdog Cracks Down on Credit Card Sneaky Fees and False Promises
Some Bonds traders bet that the Federal Reserve will cut rates in 2025 more than the market expects.
Some Bonds traders have been increasing their Options and Futures bets, expecting that the Fed will suggest a larger rate cut next year than the market anticipates. Ahead of the Fed's policy decision released in the afternoon, US Treasury bonds saw moderate gains on Wednesday. Given that a 25 basis point rate cut by the Fed is essentially seen as a certainty, the market's focus is on the Fed's latest quarterly forecast. The dot plot released in September indicated that officials expect a rate cut of 100 basis points over the next two years. However, considering that inflation data has shown persistence, the overall market bets that the Fed will lower its forecast for rate cuts next year, with swap rates suggesting that the Fed will only cut rates by 50 basis points next year. But in terms of rates
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Visa Morgan Stanley's Top Pick in Payment Sector for 2025 on Travel